239 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
German language Session
Q&A Modul
SCIENTIFIC PROGRAMME
231
WS-27
Workshop
10:00– 11:30
|
Room R12
TOPIC 3:
Psychotic disorders
Appropriate antipsychotic treatment selection in
early phase psychosis
Chair:
Phil Tibbo, Canada
Speaker:
Marc-Andre Roy, Canada
OS-61
Oral Presentation Session
10:00– 11:30
|
Room R4
TOPIC 1:
Neurocognitive disorders, organic mental
disorders, dementia
Alzheimer's disease: diagnosis and assessment
Chairs:
Carlos Augusto de Mendonça Lima, Switzerland
Frank Jessen, Germany
001
Value of amyloid imaging for differential diag-
nosis of dementia
Sabine Hellwig, Germany
Lars Frings, Tobias Bormann, Timo Spehl, Stefan Klöppel,
Werner Vach, Ralph Buchert, Philipp T. Meyer
002
Pupillometric assessment of cholinergic func-
tioning in subjects of Alzheimer's disease: a study
from India
Abdul Qadir Jilani, India
Shrikant Srivastava
003
Validation of the regression-based newly
normed SKT for the detection of MCI, depression
and dementia
Mark Stemmler, Germany
Hartmut Lehfeld
004
Limited accuracy for the detection of subjective
cognitive decline and prodromal Alzheimer's disease
based on multicenter resting-state functional con-
nectivity – results from the DZNE DELCODE study
Martin Dyrba, Germany
Coraline Metzger, Michel Grothe, Frank Jessen, Emrah
Düzel, Annika Spottke, Peter Nestor, Katharina Buerger,
Anja Schneider, Oliver Peters, Josef Priller, Jens Wiltfang,
Christoph Laske, Stefan Teipel
005
Concordance between new ELEYSIS® CSF
assays (Aß(1-42), total tau and phosphorylated tau)
and amyloid PET Imaging in BioFINDER and ADNI
Manfred Uhr, Germany
Oskar Hansson, Kaj Blennow, John Q. Trojanowski, John
Seibyl, Erik Stomrud, Tobias Bittner, Christina Rabe, Udo
Eichenlaub, Leslie M. Shaw
OS-62
Oral Presentation Session
10:00– 11:30
|
Room R5
TOPIC 3:
Psychotic disorders
Psychotic disorders: comorbidities
Chairs:
Stefan Klingberg, Germany
Wulf Rössler, Switzerland
001
Effect of insight-oriented internalized stigmati-
zation on drug compliance in patients with schizo-
phrenia and bipolar disorder
Birgül Özkan, Turkey
Gizem Gokalp
002
The Screen for Cognitive Impairment in Psy-
chiatry (SCIP) in patients with schizophrenia and
affective disorders: effects of cognitive remediation
Gabriele Sachs, Austria
Eva Maihofer, Hemma Swoboda, Andreas Erfurth
003
Comparison of neurocognitive domains in
patients with schizophrenia with and without
co-morbid obsessive compulsive disorder
Swapnajeet Sahoo, India
004
A comparative study of the economic burden
in outpatients with schizophrenia and asthma in a
Nigerian teaching hospital
Ibidunni Oloniniyi, Nigeria
Adesanmi Akinsulore, Boladale Mapayi
005
Psychosis in Parkinson's disease: are false sense
of presence and illusions psychotic symptoms?
Alakananda Dutt, India
Dipanwita Sil, Muktalekha Mukherjee, Chitrita
Sengupta, Hrishikesh Kumar
006
Worse performance on selected neuropsycho-
logical tests in abstinent schizophrenic patients with
a history of cannabis use
Krzysztof Krysta, Poland
OS-63
Oral Presentation Session
10:00– 11:30
|
Room R6
TOPIC 22:
Community and social psychiatry
Mental health care, community treatment
Chairs:
Raoul Borbé, Germany
Hans Rohlof, The Netherlands
001
Assertive community treatment – a triological
network approach in Berlin
Thomas Floeth, Germany
Susanne Ackers
002
Living museum movement as an innovative
approach for recovery from severe mental illness
Seong-Su Kim, Republic of Korea